We are live on
!
Find out more
TRCT
Tower Research Capital (TRC) Portfolio holdings
AUM
$4.08B
1-Year Est. Return
58.77%
This Fund
S&P 500
This Quarter
Est. Return
+13.23%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$3.71B
AUM Growth
+$351M
(+10%)
Cap. Flow
-$22.1M
Cap. Flow
% of AUM
-0.6%
Top 10 Holdings %
Top 10 Hldgs %
21.85%
Holding
5,705
New
584
Increased
2,919
Reduced
1,681
Closed
462
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$127M |
| 2 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$20M |
| 3 |
Palantir
PLTR
|
+$18.3M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$16.7M |
| 5 |
Diageo
DEO
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$206M |
| 2 |
Meta Platforms (Facebook)
META
|
+$37.5M |
| 3 |
Amazon
AMZN
|
+$35.5M |
| 4 |
Broadcom
AVGO
|
+$34.8M |
| 5 |
Microsoft
MSFT
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.47% |
| 2 | Financials | 11.61% |
| 3 | Healthcare | 8.42% |
| 4 | Industrials | 6.72% |
| 5 | Consumer Discretionary | 6.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Civeo
CVEO
$337M
| $11K | ﹤0.01% |
475
-468
| -50% | -$9.9K |
|
3927
Gladstone Capital
GLAD
$446M
| $10.9K | ﹤0.01% |
405
-565
| -58% | -$14.6K |
|
3928
Cenntro
CENN
$8.46M
| $10.9K | ﹤0.01% |
234
+230
| +5,750% | +$11.9K |
|
3929
Invivyd
IVVD
$203M
| $10.9K | ﹤0.01% |
15,211
-992
| -6% | -$704 |
|
3930
Cineverse
CNVS
$64.9M
| $10.9K | ﹤0.01% |
+2,274
| New | +$7.54K |
|
3931
ClearPoint Neuro
CLPT
$455M
| $10.9K | ﹤0.01% |
909
-6,827
| -88% | -$85.9K |
|
|
LAZR
3932
DELISTED
Luminar Technologies
LAZR
| $10.8K | ﹤0.01% |
3,769
-307
| -8% | -$1.17K |
|
3933
US Gold Corp
USAU
$251M
| $10.8K | ﹤0.01% |
886
-3,560
| -80% | -$39.2K |
|
3934
Telomir Pharmaceuticals
TELO
$77.7M
| $10.8K | ﹤0.01% |
8,646
+5,929
| +218% | +$13.7K |
|
3935
Cardlytics
CDLX
$22.4M
| $10.8K | ﹤0.01% |
657
+170
| +35% | +$2.94K |
|
3936
Atour Lifestyle Holdings
ATAT
$4.63B
| $10.8K | ﹤0.01% |
+331
| New | +$9.41K |
|
|
OSG
3937
Octave Specialty Group
OSG
$205M
| $10.7K | ﹤0.01% |
1,510
-1,838
| -55% | -$13.7K |
|
3938
Toast
TOST
$20.2B
| $10.7K | ﹤0.01% |
242
-296
| -55% | -$11.6K |
|
3939
SKYX Platforms
SKYX
$165M
| $10.7K | ﹤0.01% |
+10,245
| New | +$12.4K |
|
3940
GlucoTrack
GCTK
$2.87M
| $10.6K | ﹤0.01% |
+1,772
| New | +$15.6K |
|
3941
PepGen
PEPG
$201M
| $10.6K | ﹤0.01% |
9,570
+3,411
| +55% | +$4.82K |
|
3942
Direxion Daily MSCI Brazil Bull 2X ETF
BRZU
$90M
| $10.6K | ﹤0.01% |
162
-221
| -58% | -$12.6K |
|
3943
authID Inc
AUID
$9.55M
| $10.6K | ﹤0.01% |
+2,001
| New | +$11.7K |
|
3944
Acrivon Therapeutics
ACRV
$74M
| $10.5K | ﹤0.01% |
8,844
+5,754
| +186% | +$7.9K |
|
|
MAGN
3945
Magnera Corp
MAGN
$444M
| $10.5K | ﹤0.01% |
870
-7,099
| -89% | -$97.7K |
|
|
YB
3946
Yuanbao Inc
YB
$633M
| $10.5K | ﹤0.01% |
+500
| New | +$8.32K |
|
|
EZRA
3947
Reliance Global Group
EZRA
$1.94M
| $10.5K | ﹤0.01% |
141
+127
| +907% | +$6.77K |
|
|
SOL
3948
DELISTED
Emeren Group
SOL
| $10.5K | ﹤0.01% |
+5,604
| New | +$8.75K |
|
3949
Xilio Therapeutics
XLO
$60.4M
| $10.5K | ﹤0.01% |
+1,101
| New | +$11.6K |
|
|
TLN
3950
Talen Energy Corp
TLN
$17.1B
| $10.5K | ﹤0.01% |
36
-609
| -94% | -$144K |
|
Similar funds
CA
BHC
ICP
AP
BWA
BOK
JSW
SP
Tower Research Capital (TRC)'s Q2 2025 Portfolio in Review
As of Q2 2025, Tower Research Capital (TRC) held 5,705 positions worth $3.71B, up 10% from $3.36B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Tower Research Capital (TRC)'s Q2 2025 filing shows 584 new, 2,919 increased, 1,681 reduced and 462 closed positions. Its largest new stake was State Street SPDR Bloomberg 1-3 Month T-Bill ETF: 218,270 shares worth $20M. The largest sale was Invesco QQQ Trust, an estimated $206M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Tower Research Capital (TRC)'s largest Q2 2025 buy was State Street SPDR Bloomberg 1-3 Month T-Bill ETF: 218,270 shares worth $20M.
- Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q2 2025, an estimated $127M increase.
- Tower Research Capital (TRC)'s biggest Q2 2025 reduction was Invesco QQQ Trust, cutting an estimated $206M.
- Tower Research Capital (TRC) fully exited iShares S&P 500 Value ETF in Q2 2025, selling an estimated $6.43M.
- Tower Research Capital (TRC)'s ten largest holdings make up 22% of its $3.71B portfolio in Q2 2025.
- Tower Research Capital (TRC) opened 584 new positions and closed 462 in Q2 2025.
- Tower Research Capital (TRC)'s portfolio value rose 10% quarter-over-quarter to $3.71B.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.